a new oral dosage regimen and formulation of pyronaridine basing on the pharmacokinetic studies and a theoretical dosage regimen reported previously , was clinically evaluated for its therapeutic and undesirable effects on falciparum malaria patients in west hainan province , where chloroquine-resistant falciparum malaria was prevalent .
C0008269
chloroquine
C0024535
falciparum malaria